Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions - PubMed
5 hours ago
- #Alzheimer's disease
- #Neuroprotection
- #Diabetes
- Metformin shows superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease (AD).
- The study used comparative network pharmacology to evaluate 39 diabetes therapies, finding metformin most effective and semaglutide least effective in AD prevention.
- Metformin's benefits are mediated through AMPK, insulin, and adipocytokine signaling, influencing key Alzheimer's-related processes.
- Certain combination therapies (e.g., insulin glargine with lixisenatide) showed effects comparable to metformin.
- The findings support prioritizing metformin for targeted studies in high-risk diabetes patients and highlight the need for precision medicine in AD prevention trials.